199657-29-9
199657-29-9 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | DMSO：45.8（最大浓度 mg/mL）；100.01（最大浓度 mM） |
| 形态 | Solid |
| 颜色 | White to off-white |
199657-29-9 用途与合成方法
|
hHDAC3 157 nM (IC 50 ) |
hHDAC1 198 nM (IC 50 ) |
hHDAC11 292 nM (IC 50 ) |
hHDAC6 315 nM (IC 50 ) |
hHDAC2 325 nM (IC 50 ) |
hHDAC10 340 nM (IC 50 ) |
hHDAC7 524 nM (IC 50 ) |
hHDAC5 532 nM (IC 50 ) |
hHDAC9 541 nM (IC 50 ) |
hHDAC8 854 nM (IC 50 ) |
hHDAC4 1059 nM (IC 50 ) |
HD1-B 7.5 nM (IC 50 ) |
HD1-A 16 nM (IC 50 ) |
HD2 10 nM (IC 50 ) |
Givinostat (ITF2357) suppresses total LPS-induced IL-1β production robustly compared with the reduction by ITF3056. At 25, 50, and 100 nM, Givinostat reduces IL-1β secretion more than 70%. Givinostat suppresses the production of IL-6 in PBMCs stimulated with TLR agonists as well as the combination of IL-12 plus IL-18. IL-6 secretion decreases to 50% at 50 nM Givinostat, but at 100 and 200 nM, there is no reduction. Givinostat (ITF-2357) inhibits JS-1 cell proliferation in a concentration-dependent manner in the CCK-8 assay. Treatment with Givinostat (ITF-2357) ≥500 nM is associated with significant inhibition of JS-1 cell proliferation. Also, the cell inhibition rate significantly differs between the group cotreated with Givinostat (ITF-2357) ≥250 nM plus LPS and the group without LPS treatment.
Givinostat (ITF2357) at 10 mg/kg is used as a positive control and reduces serum TNFα by 60%. Pretreatment of Givinostat (ITF-2357) starting at 0.1 mg/kg significantly reduces the circulating TNFα by nearly 90%. To achieve a significant increase in serum IL-1β production, a higher dose of LPS is injected (10 mg/kg), and blood is collected after 4 h.
199657-29-9 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-14842A | 199657-29-9 | 199657-29-9 | 5 mg | 890 |
| 2026-09-15 | HY-14842A | 199657-29-9 | 199657-29-9 | 10 mM * 1 mLin DMSO | 897 |
